S
Silvio E. Inzucchi
Researcher at Yale University
Publications - 511
Citations - 64889
Silvio E. Inzucchi is an academic researcher from Yale University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 92, co-authored 424 publications receiving 54101 citations. Previous affiliations of Silvio E. Inzucchi include University of Toronto & American Diabetes Association.
Papers
More filters
Journal ArticleDOI
A Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients with Type 2 Diabetes at High Cardiovascular Risk (the SIMPLE Trial).
Emil Wolsk,Mikkel Jürgens,Morten Schou,Mads Ersbøll,Philip Hasbak,A. Kjær,Bo Zerahn,Niels Høgh Brandt,Peter Haulund Gæde,Peter Rossing,Jens Faber,Silvio E. Inzucchi,Caroline Kistorp,Finn Gustafsson +13 more
TL;DR: Treatment with empagliflozin for 13 weeks in patients with type 2 diabetes at high cardiovascular risk did not reduce left heart filling pressure more than placebo at submaximal exercise, and at rest, it was observed that emPag liflozin reduced PCWP at a magnitude of clinical significance.
Journal ArticleDOI
Spontaneous resolution of primary hypercortisolism of cushing disease after pituitary hemorrhage.
TL;DR: A case of spontaneous resolution of primary hypercortisolism from Cushing disease (CD) from symptomatic hemorrhage within an ACTH-secreting pituitary adenoma, or PA is reported.
Journal ArticleDOI
Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes.
Journal ArticleDOI
Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER
Xiaowen Wang,Muthiah Vaduganathan,Brian Claggett,Sheila M. Hegde,Maria A. Pabon,Ian J. Kulac,Orly Vardeny,Eileen O'Meara,Shelley Zieroth,Tzvetana Katova,Martina M. McGrath,Anne-Catherine Pouleur,Pardeep S. Jhund,Akshay S. Desai,Silvio E. Inzucchi,Mikhail Kosiborod,W. De Boer,Lars Køber,Marc S. Sabatine,Felipe Martinez,Piotr Ponikowski,Adrian F. Hernandez,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon,Carolyn S.P. Lam +25 more
TL;DR: In this article , the authors assess the effect of sex on the efficacy and safety of dapagliflozin across the spectrum of left ventricular ejection fraction and find no sex-related differences in serious adverse events, adverse events or drug discontinuation attributable to adverse events.
Journal ArticleDOI
Estimated Event-Free Survival Benefits with Dapagliflozin in HF with Mildly Reduced or Preserved Ejection Fraction.
Muthiah Vaduganathan,Brian Claggett,Pardeep S. Jhund,W. De Boer,Adrian F. Hernandez,Silvio E. Inzucchi,Mikhail Kosiborod,Carolyn S.P. Lam,Felipe Martinez,Akshay S. Desai,Dan Lindholm,Magnus Petersson,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon +14 more
TL;DR: In this article , the authors applied validated nonparametric age-based methods to extrapolate potential gains in survival free from the primary endpoint (cardiovascular death or worsening heart failure event) from long-term use of dapagliflozin.